India Healthcare: US Generics Reset? Pricing Trough Ends, New Entrants Dry Up, Cashflows Lift for Integrated Companies With Scale

Research evidence excerpt

India Healthcare: US Generics Reset? Pricing Trough Ends, New Entrants Dry Up, Cashflows Lift for Integrated Companies With Scale

30 June 2026

India Healthcare

India Healthcare: US Generics Reset? Pricing Trough Ends, New

Entrants Dry Up, Cashflows Lift for Integrated Companies With

Scale

During the last week, Aurobindo Pharma and Dr Reddy Labs (Not covered) had a fresh wave Nandan Kulkarni

+91 22 6842 1436 of Form 483s being issued by the USFDA to their core manufacturing sites in Southern

nandan.kulkarni@bernsteinsg.com India. Despite these sites holding a key to important filings like Abatacept for Dr. Reddy’s, or

complex injectable portfolio for Aurobindo, the markets reacted to this news in a completely

Shirsh Sawarna opposite way on the week’s opening with both of these stocks moving UP rather than

+91 226 842 1492

shirsh.sawarna@bernsteinsg.com DOWN. Aurobindo closed about one and a half percentage while Dr. Reddy’s around five

percentage over the last week. Why? We believe the driver is a potential improvement

in Indian Biopharma’s US portfolio profitability, a macro trend yet to be fully priced

in than a stock-specific trigger.

In our Initiation report, we had highlighted the disease burden warranting a more favorable

regulatory policies globally including the US and had estimated a growing baseline in US

portfolio against consensus continuing to model a typical erosion in topline and margins.

Against the backdrop of geopolitical volatility, macro inflation, and rewiring of global supply

chains over the last few quarters, US generic supply is tightening in clinically essential

drugs, especially sterile injectables, oral liquids, acute hospital baskets and we believe this

is the beginning of a deeper and longer chain reaction. The tip of the shortage iceberg is